BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 16966409)

  • 1. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
    Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
    Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
    Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
    Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
    Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
    Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with monoclonal antibodies against Clostridium difficile toxins.
    Lowy I; Molrine DC; Leav BA; Blair BM; Baxter R; Gerding DN; Nichol G; Thomas WD; Leney M; Sloan S; Hay CA; Ambrosino DM
    N Engl J Med; 2010 Jan; 362(3):197-205. PubMed ID: 20089970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
    Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
    Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
    Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
    Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.
    Kink JA; Williams JA
    Infect Immun; 1998 May; 66(5):2018-25. PubMed ID: 9573084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.
    Cohen OR; Steele JA; Zhang Q; Schmidt DJ; Wang Y; Hamel PE; Beamer G; Xu B; Tzipori S
    PLoS One; 2014; 9(10):e111075. PubMed ID: 25347821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.
    Andersen KK; Strokappe NM; Hultberg A; Truusalu K; Smidt I; Mikelsaar RH; Mikelsaar M; Verrips T; Hammarström L; Marcotte H
    Infect Immun; 2016 Feb; 84(2):395-406. PubMed ID: 26573738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant lipoprotein-based vaccine candidates against C. difficile infections.
    Huang JH; Wu CW; Lien SP; Leng CH; Hsiao KN; Liu SJ; Chen HW; Siu LK; Chong P
    J Biomed Sci; 2015 Aug; 22(1):65. PubMed ID: 26245825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clostridium difficile--beyond antibiotics.
    Kyne L
    N Engl J Med; 2010 Jan; 362(3):264-5. PubMed ID: 20089977
    [No Abstract]   [Full Text] [Related]  

  • 14. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
    Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
    Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
    Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.
    Katchar K; Taylor CP; Tummala S; Chen X; Sheikh J; Kelly CP
    Clin Gastroenterol Hepatol; 2007 Jun; 5(6):707-13. PubMed ID: 17544998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters.
    Geric B; Carman RJ; Rupnik M; Genheimer CW; Sambol SP; Lyerly DM; Gerding DN; Johnson S
    J Infect Dis; 2006 Apr; 193(8):1143-50. PubMed ID: 16544255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting.
    Quemeneur L; Petiot N; Arnaud-Barbe N; Hessler C; Pietrobon PJ; Londoño-Hayes P
    Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29632249
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea.
    Jiang ZD; Garey KW; Price M; Graham G; Okhuysen P; Dao-Tran T; LaRocco M; DuPont HL
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):964-8. PubMed ID: 17618838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
    Permpoonpattana P; Hong HA; Phetcharaburanin J; Huang JM; Cook J; Fairweather NF; Cutting SM
    Infect Immun; 2011 Jun; 79(6):2295-302. PubMed ID: 21482682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.